The recently launched National Intellectual Property Rights (IPR) policy is a step in the right direction and towards creating an ecosystem for innovation, and it also brings clarity on India's position on IPR framework, he said, adding that a "not so friendly" clinical research environment prevails in the country.
"There is enormous pendency of patent applications in India. It takes around 6-8 years to clear patent here while outside of the country the time taken is 2-3 years whether it's US, Japan or Europe. This is the situation we are facing," Khorakiwala said in a conference call today.
"Weightage should be given to a product patents as compared to a process patent application. There should be a fast track system to clear such patents," Khorakiwala said.
Giving example of his own company, he said that the drug firm has filed around 2,178 patents in the last 10-12 years and received just 79 approvals so far in India.
"If we talk about the recent filings, over the last 12 months we filed 217 patent applications. We got 121 cleared abroad while only 8 were granted by authorities in India." Khorakiwala said.
"In the last two years we have 400 trademark applications pending. Globally such applications are cleared in 1-1.5 years while in India the time taken is over three years," Khorakiwala noted.
Recently, talking about steps to reduce pendency of applications, Union Commerce and Industry Minister Nirmala Sitharaman had said the ministry is recruiting people and giving them training and also modernising offices.
The total number of patent applications and trademark registration requests pending as on February 1 were 2,37,029 and 5,44,171, respectively.
Commenting on the difficulties faced by the industry in conducting clinical trials in India, Khorakiwala said: "Our current system is not friendly towards clinical research work and that is why we prefer getting it done outside the country. Here the DCGI takes six months just to clear the protocol while it's just few weeks outside the country."
IPR policy with a tagline of 'Creative India, Innovative India' to incentivise entrepreneurship, creativity and innovation and curb manufacturing and sale of counterfeits.
The seven objectives of the policy include stimulation of generation of IPRs, need for strong and effective laws and strengthening enforcement and adjudicatory mechanisms to combat infringements.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
